Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISTH 2022 | The safety and efficacy of eptacog beta in patients with hemophilia

Alok Srivastava • 11 Jul 2022
ISTH 2022
Hemophilia Eptacog alfa Eptacog beta

Alok Srivastava, MD, FRACP, FRCPA, FRCP, Christian Medical College, Vellore, India, shares some insights into the safety and efficacy of eptacog beta for the resolution of bleeding episodes in patients with hemophilia A or B with inhibitors. This interview took place at the 30th Congress of the International Society on Thrombosis and Haemostasis (ISTH) 2022 held in London, UK.

More from Alok Srivastava

How hemophilia care has changed over the years
1:58
How hemophilia care has changed over the years
Alok Srivastava • 11 Jul 2022
The promise of fitusiran for the treatment of patients with hemophilia A and B
1:48
The promise of fitusiran for the treatment of patients with hemophilia A and B
Alok Srivastava • 11 Jul 2022
The safety and efficacy of fitusiran prophylaxis in patients with hemophilia A and B
1:43
The safety and efficacy of fitusiran prophylaxis in patients with hemophilia A and B
Alok Srivastava • 11 Jul 2022

Related Videos

Importance of long-term surveillance after gene therapy in patients with hemophilia
5:45
Importance of long-term surveillance after gene therapy in patients with hemophilia
Radek Kaczmarek • 20 Jul 2026
Emerging non-AAV gene therapy strategies in hemophilia: opportunities and challenges
4:58
Emerging non-AAV gene therapy strategies in hemophilia: opportunities and challenges
Radek Kaczmarek • 20 Jul 2026
Ongoing challenges associated with using AAV-based gene therapy in hemophilia
5:18
Ongoing challenges associated with using AAV-based gene therapy in hemophilia
Radek Kaczmarek • 20 Jul 2026
Understanding potential malignancy risk following AAV gene therapy in hemophilia
7:23
Understanding potential malignancy risk following AAV gene therapy in hemophilia
Radek Kaczmarek • 20 Jul 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals